The Conversation (0)
Regenicin today announces a new agreement with Pure Med Farma: the former will supply closed herd collagen, necessary for the production of NovaDerm.
Regenicin (OTC:RGIN) today announces a new agreement with Pure Med Farma: the former will supply closed herd collagen, necessary for the production of NovaDerm.
According to the press release:
“The agreement with PMF states Regenicin will receive priority pricing and guaranteed inventory availability. This is a key milestone, as guidance documents from the U.S. Food and Drug Administration (FDA) clearly state that any product requesting approval to enter clinical trials will be denied until the applicant presents evidence that components derived from animal sources were obtained from closed herds.”
Regenicin’s CEO, Randall McCoy, said the following:
“Using collagen that comes from a bovine closed herd provides a significant breakthrough in safety, as closed herd quality systems are designed to minimize exposure to pathogens which could be transferred to humans when using animal components for healthcare.”